ACARIX Stock Overview
A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Acarix AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.24 |
| 52 Week High | SEK 0.60 |
| 52 Week Low | SEK 0.17 |
| Beta | 1.46 |
| 1 Month Change | -15.37% |
| 3 Month Change | 0% |
| 1 Year Change | -1.84% |
| 3 Year Change | -63.44% |
| 5 Year Change | -88.08% |
| Change since IPO | -98.53% |
Recent News & Updates
Recent updates
We Think Acarix (STO:ACARIX) Needs To Drive Business Growth Carefully
Jan 03
Will Acarix (STO:ACARIX) Spend Its Cash Wisely?
Jun 13Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation
Jun 12We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate
Oct 27Will Acarix (STO:ACARIX) Spend Its Cash Wisely?
Jun 22Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth
Mar 04Shareholder Returns
| ACARIX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 10.4% | 6.3% | 9.2% |
| 1Y | -1.8% | -20.8% | -4.5% |
Return vs Industry: ACARIX exceeded the Swedish Medical Equipment industry which returned -20.8% over the past year.
Return vs Market: ACARIX exceeded the Swedish Market which returned -4.5% over the past year.
Price Volatility
| ACARIX volatility | |
|---|---|
| ACARIX Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 13.9% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: ACARIX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ACARIX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 14 | Aamir Mahmood | www.acarix.com |
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.
Acarix AB (publ) Fundamentals Summary
| ACARIX fundamental statistics | |
|---|---|
| Market cap | SEK 248.38m |
| Earnings (TTM) | -SEK 66.19m |
| Revenue (TTM) | SEK 6.20m |
41.1x
P/S Ratio-3.8x
P/E RatioIs ACARIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACARIX income statement (TTM) | |
|---|---|
| Revenue | SEK 6.20m |
| Cost of Revenue | SEK 607.00k |
| Gross Profit | SEK 5.60m |
| Other Expenses | SEK 71.78m |
| Earnings | -SEK 66.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 90.21% |
| Net Profit Margin | -1,067.19% |
| Debt/Equity Ratio | 0% |
How did ACARIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 22:11 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acarix AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Ludvig Svensson | Redeye |
| Filip Einarsson | Redeye |